



Source details

African Journal of Infectious Diseases

Scopus coverage years: from 2010 to Present

Publisher: African Ethnomedicines Network

ISSN: 2006-0165

Subject area: Medicine: Infectious Diseases

Source type: Journal

[View all documents >](#)

[Set document alert](#)

[Save to source list](#)

CiteScore 2021

2.2



SJR 2021

0.256



SNIP 2021

0.569



[CiteScore](#) [CiteScore rank & trend](#) [Scopus content coverage](#)

i Improved CiteScore methodology ✕

CiteScore 2021 counts the citations received in 2018-2021 to articles, reviews, conference papers, book chapters and data papers published in 2018-2021, and divides this by the number of publications published in 2018-2021. [Learn more >](#)

CiteScore 2021 ▾

$$2.2 = \frac{179 \text{ Citations 2018 - 2021}}{81 \text{ Documents 2018 - 2021}}$$

Calculated on 05 May, 2022

CiteScoreTracker 2022 ⓘ

$$0.5 = \frac{25 \text{ Citations to date}}{50 \text{ Documents to date}}$$

Last updated on 05 August, 2022 • Updated monthly

CiteScore rank 2021 ⓘ

Category	Rank	Percentile
Medicine		
Infectious Diseases	#197/295	33rd

[View CiteScore methodology >](#) [CiteScore FAQ >](#) [Add CiteScore to your site](#)

About Scopus

[What is Scopus](#)
[Content coverage](#)
[Scopus blog](#)
[Scopus API](#)
[Privacy matters](#)

Language

[日本語版を表示する](#)
[查看简体中文版本](#)
[查看繁體中文版本](#)
[Просмотр версии на русском языке](#)

Customer Service

[Help](#)
[Tutorials](#)
[Contact us](#)


ELSEVIER

[Terms and conditions](#) ↗ [Privacy policy](#) ↗

Copyright © [Elsevier B.V](#) ↗. All rights reserved. Scopus® is a registered trademark of Elsevier B.V.

We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the [use of cookies](#) ↗.



also developed by scimago:  SCIMAGO INSTITUTIONS RANKINGS


SJR Scimago Journal & Country Rank

Home Journal Rankings Country Rankings Viz Tools Help About Us

Disease landscape & forecast
 Autism market forecast
 Disease landscape and forecast market report

clarivate.com [OPEN](#)

African Journal of Infectious Diseases

<p>COUNTRY</p> <p>Nigeria</p> <p></p>	<p>SUBJECT AREA AND CATEGORY</p> <p>Medicine └ Infectious Diseases</p>	<p>PUBLISHER</p> <p>Obafemi Awolowo University</p>	<p>H-INDEX</p> <p>14</p>
<p>PUBLICATION TYPE</p> <p>Journals</p>	<p>ISSN</p> <p>20060165</p>	<p>COVERAGE</p> <p>2010-2021</p>	<p>INFORMATION</p> <p>Homepage How to publish in this journal cyprian.onyeji@unn.edu.ng</p>

IJS DR Research Journal

submit paper
for publication

[Open](#)

SCOPE

The "African Journal of Infectious Disease (AJID)" is a peer-reviewed, multidisciplinary, international, scientific journal that provides rapid publication of articles on Infectious Diseases of man and domestic animals. The Journal welcomes submission of articles that meet the general criteria of significance and scientific excellence. Papers will be published approximately two-to-three months after acceptance.

 Join the conversation about this journal

Clarivate - Market report

Chronic market forecast
 Disease landscape and forecast market report








clarivate.com

[OPEN](#)

FIND SIMILAR JOURNALS

options

<p>1 BMC Infectious Diseases GBR</p> <p>61% similarity</p>	<p>2 Pathogens and Global Health GBR</p> <p>58% similarity</p>	<p>3 Tropical Medicine and International Health GBR</p> <p>55% similarity</p>	<p>4 International Journal of Infectious Diseases NLD</p> <p>54% similarity</p>	<p>5 Southeast Asian Journal of Tropical Medicine and Public Health THA</p> <p>52% similarity</p>
--	--	---	---	---



African Journal of Infectious Diseases

← Show this widget in your own website

Just copy the code below and paste within your html code:

`https://www.scimagojr.com`

powered by scimagojr.com

SCImago Graphica

Explore, visually communicate and make sense of data with our **new data visualization tool**.

Metrics based on Scopus® data as of April 2022



Dr. Dina T. Sarhan 2 years ago

Does the journal provide fast track publication for articles related to COVID-19. And if yes, is there any extra fees for fast track?

[reply](#)



Melanie Ortiz 2 years ago

SCImago Team

Dear Dina,
thank you for contacting us.
Unfortunately, we cannot help you with your request, we suggest you to visit the journal's homepage (See submission/author guidelines) or contact the journal's editorial staff, so they could inform you more deeply.
Best Regards, SCImago Team

Leave a comment

Name

Email

(will not be published)

Submit

The users of Scimago Journal & Country Rank have the possibility to dialogue through comments linked to a specific journal. The purpose is to have a forum in which general doubts about the processes of publication in the journal, experiences and other issues derived from the publication of papers are resolved. For topics on particular articles, maintain the dialogue through the usual channels with your editor.

Developed by:



Powered by:

Scopus

Follow us on [@ScimagoJR](#)

Scimago Lab, Copyright 2007-2022. Data Source: Scopus®

EST MODUS IN REBUS

Horatio (Satiro 1, 1, 106)

[Edit Cookie Consent](#)

Vol. 12 No. 1S (2018): Special Issue

Published: 2018-03-07

Articles

IN VITRO STUDIES ON HEME OXYGENASE-1 AND P24 ANTIGEN HIV-1 LEVEL AFTERHYPERBARIC OXYGEN TREATMENTOFHIV-1 INFECTED ON PERIPHERAL BLOOD MONONUCLEAR CELLS (PBMCS)

Retno Budiarti, Kuntaman Kuntaman, Muhammad Nasronudin, muhammad guritno suryokusumo, Siti Qamariyah Khairunisa

1-6

 [Fulltext.pdf](#)

GENOTYPING OF HUMAN PAPPILOMAVIRUS IN CERVICAL PRECANCEROUS LESION AND SQUAMOUS CELL CARCINOMA AT DR. SOETOMO HOSPITAL, SURABAYA, INDONESIA

Gondo Mastutik, Rahmi Alia, Alphania Rahniayu, Anny Setijo Rahaju, Nila Kurniasari, Suhartono Taat Putra

7-12

 [Fulltext.pdf](#)

DETERMINATION OF ENVIRONMENTAL FACTORS AFFECTING DENGUE INCIDENCE IN SLEMAN DISTRICT, YOGYAKARTA, INDONESIA

Tri Wulandari Kesetyaningsih, Sri Andarini, Sudarto Sudarto, Henny Pramodyo

13-35

 [Fulltext.pdf](#)

ANTIVIRAL ACTIVITY OF *Justicia gendarussa* Burm.f. LEAVES AGAINST HIV-INFECTED MT-4 CELLS

Agustinus Widodo, Prihartini Widiyanti, Bambang Prajogo

36-43

 [Fulltext.pdf](#)

ACANTHAMOEBA SPS-11 PHAGOCYTOTIC ACTIVITY ON MYCOBACTERIUM LEPRAE IN DIFFERENT NUTRIENT CONDITIONS

Sepling Paling, Ratna Wahyuni, DEA Ni'matuzahroh, Dwi Winarni, M. KES Iswahyudi, Linda Astari, Dinar Adriaty, Indropo Agusni, Shinzo Izumi

44-48

 [Fulltext.pdf](#)

CD4+ AND CD8+ T-CELLS EXPRESSING INTERFERON GAMMA IN ACTIVE PULMONARY TUBERCULOSIS PATIENTS

Betty Agustina Tambunan, Hery Priyanto, Jusak Nugraha, Soedarsono Soedarsono

49-53

 [Fulltext.pdf](#)

THE ROLE OF PSYCHOLOGICAL WELL-BEING IN BOOSTING IMMUNE RESPONSE: AN OPTIMAL EFFORT FOR TACKLING INFECTION

Abdurachman Latief, Netty Herawati

54-61

 [Fulltext.pdf](#)

ANTIBACTERIAL ACTIVITY OF DRACONTOMELON DAO EXTRACTS ON METHICILLIN-RESISTANT S. AUREUS (MRSA) AND E. COLI MULTIPLE DRUG RESISTANCE (MDR)

Yuniati Yuniati, Nurul Hasanah, Sjarif Ismail, Silvia Anitasari, Swandari Paramita

62-67

 [Fulltext.pdf](#)

INCREASED APOPTOSIS SKULL OF PUPS BORN TO TOXOPLASMA GONDII-INFECTED MICE ASSOCIATED WITH INCREASED EXPRESSION OF INTERFERON GAMMA, BUT NOT TUMOR NECROSIS FACTOR ALFA

Lucia Tri Suwanti, Mufasirin Mufasirin

68-71

 [Fulltext.pdf](#)

ADDITION OF ANTI- *Toxoplasma gondii* MEMBRANE IMMUNOGLOBULIN Y TO REDUCE NECROTIC INDEX IN MICE'S LIVER

Heni Puspitasari, Lucia T. Suwanti, Mufasirin Djaeri

72-75

 [Fulltext.pdf](#)

SEROPREVALENCE AND RISK FACTOR OF TOXOPLASMOSIS IN SCHIZOPHRENIA PATIENTS REFERRED TO GRHASIA PSYCHIATRIC HOSPITAL, YOGYAKARTA, INDONESIA

Nina Difla Muflikhah, Supargiyono Supargiyono, Wayan Tunas Artama

76-82

 [Fulltext.pdf](#)

CONCOMITANT SEXUALLY TRANSMITTED DISEASES IN PATIENTS WITH DIAGNOSED HIV/AIDS: A RETROSPECTIVE STUDY

Densy Violina Harnanti, Afif Nurul Hidayati, Muhammad Miftahussurur

83-89

[Fulltext.pdf](#)

RISK FACTORS OF VULVOVAGINAL CANDIDIASIS IN DERMATO-VENERELOGY OUTPATIENTS CLINIC OF SOETOMO GENERAL HOSPITAL, SURABAYA, INDONESIA

Dharin Serebrina Arfiputri, Afif Nurul Hidayati, Samsriyaningsih Handayani, Evy Ervianti

90-94

[Fulltext.pdf](#)

COMPARISON OF ANTI BACTERIAL EFFICACY OF PHOTODYNAMIC THERAPY AND DOXYCYCLINE ON AGGREGATIBACTER ACTINOMYCETEMCOMITANS

Ernie Maduratna Setiawatie, Vina Puji Lestari, Suryani Dyah Astuti

95-103

[Fulltext.pdf](#)

EVALUATION OF THE ANTIGENICITY AND IMMUNOGENICITY OF *Eimeria tenella* BY REPRODUCTIVE INDEX AND HISTOPATHOLOGICAL CHANGES OF CECAL COCCIDIOSIS VIRULENT LIVE VACCINE IN BROILER CHICKENS

Endang Suprihati, Muchammad Yunus

104-110

[Fulltext.pdf](#)

DETERMINATION OF EFFECTIVE DOSE OF ANTIMALARIAL FROM CASSIA SPECTABILIS LEAF ETHANOL EXTRACT IN PLASMODIUM BERGHEI-INFECTED MICE

Wiwied Ekasari, Tutik Sri Wahyuni, Heny Arwaty, Nindya T. Putri

111-115

[Fulltext.pdf](#)

A NEW COPPER (II)-IMIDAZOLE DERIVATIVE EFFECTIVELY INHIBITS REPLICATION OF DENV-2 IN VERO CELL

Teguh Hari Sucipto, Siti Churrotin, Harsasi Setyawati, Fahimah Martak, Kris Cahyo Mulyatno, Ilham Harlan Amarullah, Tomohiro Kotaki, Masanori Kameoka, Masanori Kameoka, Subagyo Yotopranoto, Soengeng Soegijanto

116-119

[Fulltext.pdf](#)

COMPARISON OF MULTIPLEX SINGLE ROUND PCR AND MICROSCOPY IN DIAGNOSIS OF AMOEBIASIS

BS Sri-Hidajati, Sukmawati Basuki, Suhintam Pusarawati, Kusmartisnawati Kusmartisnawati, Lynda Rossyanti, Sri Wijayanti Sulistyowati, Dwi Peni Kartikasari, Heny Arwati, Indah Tantar, Alpha Fardah, Andy Darma, Retno Handajani, Subijanto Marto Soedarmo

120-126

[Fulltext.pdf](#)

CLONING AND EXPRESSION OF MCE1A GENE FROM MYCOBACTERIUM TUBERCULOSIS BEIJING AND H37RV STRAIN FOR VACCINE CANDIDATE DEVELOPMENT

Desi Indriarini, Andriansjah Rukmana, Andi Yasmon
127-132

 [Fulltext.pdf](#)

EFFECT OF VARYING INCUBATION PERIODS ON CYTOTOXICITY AND VIRUCIDAL ACTIVITIES OF *Justicia gendarussa* Burm.f. LEAF EXTRACT ON HIV-INFECTED MOLT-4 CELLS

Prihartini Widiyanti, Bambang Prajogo, Agustinus Widodo
133-139

 [Fulltext.pdf](#)

IN SILICO SCREENING AND BIOLOGICAL EVALUATION OF THE COMPOUNDS OF *Justicia gendarussa* LEAVES EXTRACT AS INTERFERON GAMMA INDUCER: A STUDY OF ANTI HUMAN IMMUNODEFICIENCY VIRUS (HIV) DEVELOPMENT

Restry Sinansari, Bambang EW Prajogo, Prihartini Widiyanti
140-147

 [Fulltext.pdf](#)

ISOLATION AND IDENTIFICATION OF BRUCELLA SUIIS IN PIGS AS ZONOTIC DISEASE IN ENDEMIC AREAS OF EAST JAVA, INDONESIA

Emy S Koestanti, Wiwik Misaco, Sri Chusniati, Lilik Maslachah
148-151

 [Fulltext.pdf](#)

Intructions for Authors

INSTRUCTIONS FOR AUTHORS

Babatunde O Olagunju
152-158

 [FullText.PDF](#)

[Make a Submission](#)


Information

For Readers

For Authors

For Librarians

Keywords



Most Read Articles (last 30 days)

HOW MISUSE OF ANTIMICROBIAL AGENTS IS EXACERBATING THE CHALLENGES FACING SOMALIA'S PUBLIC HEALTH

👁 95

A CROSS-SECTIONAL ASSESSMENT OF PHARMACISTS' KNOWLEDGE, ATTITUDE AND PRACTICE OF PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN TWO NIGERIAN TEACHING HOSPITALS

👁 42

RDT- AND MICROSCOPIC-BASED TRENDS OF MALARIA AMONG LOCAL AND MIGRANT POPULATIONS IN THE PROVINCE OF CENTRAL KALIMANTAN, INDONESIA DURING 2017-2020

👁 25

KNOWLEDGE, ATTITUDE AND RISK PERCEPTION OF COVID-19 AMONG NIGERIANS

👁 21

PROSPECTS OF LASSA FEVER CANDIDATE VACCINES

👁 20



All articles of the African Journal of Infectious Diseases (AJID) are published under the terms of the [Attribution 4.0 International \(CC BY 4.0\)](#), which allows users to copy, distribute and transmit an article, adapt the article and make commercial use of the article. The CC BY license permits commercial and non-commercial re-use of an open access article, as long as the author is properly attributed.

OJS Support, and Customization by | [OJS-Services.com](#)

Editorial Team

Managing Editor

Prof. Cyprian O. Onyeji, Department of Pharmaceutical and Medicinal Chemistry Faculty of Pharmaceutical Sciences, University of Nigeria, Nsukka. Nigeria. E-mail: cyprian.onyeji@unn.edu.ng

Editorial Assistants

Ms Omolade Olaboye, African Journal of Infectious Diseases COJA VILLA, 7, Road 1, Otun Maye Square, Ajebamidele, Ile-Ife, Osun State, Nigeria. E-mail: omolade@athmsi.org, Nigeria

Mr. Hammed Ibraheem, African Journal of Infectious Diseases, COJA VILLA, 7, Road 1, Otun Maye Square, Ajebamidele, Ile-Ife, Osun State, Nigeria. E-mail: hammed@athmsi.org, Nigeria

Associate Editors

Prof. Ademola OLANIRAN, University of KwaZulu-Natal, Durban, South Africa E-mail: olanirana@ukzn.ac.za, South Africa

Prof. Francesca MANCIANTI, Faculty of Medicine, University of Pisa, Italy E-mail: francesca.mancianti@unipi.it, Italy

Dr. Emel SONMEZ, Anadolu University, Eskisehir, Turkey E-mail: emls222224@gmail.com, Turkey

Prof. wang HUI, Chinese Academy of Agricultural Sciences, Gansu, China. E-mail: wanghui01@caas.cn, China

Editors-in-Chief

Prof. Anthony O. ONIPEDE, Department of Medical Microbiology & Parasitology, Faculty of Basic Medical Sciences, College of Health sciences, Obafemi Awolowo University, Ile-ife, Osun-State, Nigeria. E-mail: aonipede@oauife.edu.ng, Nigeria

Dr. Gbola OLAYIWOLA, Department of Clinical Pharmacy, Faculty of Pharmacy, Obafemi Awolowo University, Ile-Ife, Nigeria. E-mail: gbolaolayiwola@yahoo.com, Nigeria

Editorial Board

Dr. Saajida Mahomed, University of KwaZulu-Natal, Durban, South Africa. E-mail: mahomeds@ukzn.ac.za

Dr. Ahmed Adu-Oppong, Georgia Southern University, USA E-mail: aaduoppong@georgiasouthern.edu, United States

Prof. Vincent P. K. Titanji, University of Buea, Cameroon. E-mail: vpk.titanji@yahoo.com, Cameroon

Professor Phyllis J KANKI, Department of Immunology & Infectious Disease Harvard School of Public Health, USA. E-mail: pkanki@hsph.harvard.edu, United States

Dr. Celsus Sente, Makerere University, Kampala, Uganda. E-mail: csehnte@covab.mak.ac.ug, Uganda

Dr. Babajide sadiq, Florida A&M University, USA. E-mail: babajidesadiq@yahoo.com, United States

Dr Sharlene Govender, Department of Biochemistry & Microbiology Nelson Mandela Metropolitan University Port Elizabeth South Africa. E-mail: sharlene.govender@nmmu.ac.za, South Africa

Dr. Alok Kumar, University of the West Indies, Cave Hill, Jamaica. E-mail: alokkumar.uwichill@gmail.com

Prof. Chrispinus Mulambalah Siteti, Moi University, School of Medicine, Kitale, Kenya. E-mail: csmulambalah@gmail.com

Prof. Megbaru Alemu, Bahir Dar University Department of Microbiology, Immunology & Parasitology, Ethiopia. E-mail: mgbeyney@gmail.com, Ethiopia

Dr. Balram Ji Omar, Department of Microbiology All India Institute Of Medical Sciences Rishikesh, India. E-mail: drbalramaiims@gmail.com, India

Dr. Josyline Kaburi, University of Nairobi, Kenya. E-mail: jeirindi@kemri.org, Kenya

Dr Ezekiel Olugbenga Akinkunmi, Department of Pharmarmaceutics, Obafemi Awolowo Unversity, Ile-Ife, Nigeria. E-mail: akinkeroo@yahoo.com, Nigeria

Dr. Frank Onyambu, Kenya Medical Research Institute, PO Box 29408 NAIROBI -00100, Kenya. E-mail: frank.onyambu@iscb.org, Kenya

Dr. Suresh G. Joshi, Division of Infectious Diseases, Thomas Jefferson University, Philadelphia, PA 19107, USA' E-mail: surejoshi@yahoo.com

[Make a Submission](#)

Information

[For Readers](#)

[For Authors](#)

[For Librarians](#)

Keywords

Most Read Articles (last 30 days)

[HOW MISUSE OF ANTIMICROBIAL AGENTS IS EXACERBATING THE CHALLENGES FACING SOMALIA'S PUBLIC HEALTH](#)

[95](#)

[A CROSS-SECTIONAL ASSESSMENT OF PHARMACISTS' KNOWLEDGE, ATTITUDE AND PRACTICE OF PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN TWO NIGERIAN TEACHING HOSPITALS](#)

[42](#)

[RDT- AND MICROSCOPIC-BASED TRENDS OF MALARIA AMONG LOCAL AND MIGRANT POPULATIONS IN THE PROVINCE OF CENTRAL KALIMANTAN, INDONESIA DURING 2017-2020](#)

[25](#)

[KNOWLEDGE, ATTITUDE AND RISK PERCEPTION OF COVID-19 AMONG NIGERIANS](#)

[21](#)

PROSPECTS OF LASSA FEVER CANDIDATE VACCINES

 20

DETERMINATION OF EFFECTIVE DOSE OF ANTIMALARIAL FROM *CASSIA SPECTABILIS* LEAF ETHANOL EXTRACT IN *PLASMODIUM BERGHEI*-INFECTED MICE

Wiwied Ekasari^{1*}, Tutik Sri Wahyuni¹, Heny Arwaty², Nindya T. Putri¹

¹Departement of Pharmacognosy and Phytochemistry , Faculty of Pharmacy, Airlangga University, Surabaya, Indonesia; ²Faculty of Medicine, Airlangga University, Surabaya, Indonesia.

*Corresponding Author E-mail: wiwiedeka@hotmail.com

Article History

Received: March. 16, 2017

Revised Received: Oct. 13, 2017

Accepted: Oct. 17, 2017.

Published Online: March. 07, 2018,

Abstract

Background: The preliminary study on antimalarial activity of the ethanol extract of *Cassia spectabilis* leaves against *Plasmodium berghei* has been carried out by *in vivo* experiment. It was demonstrated that ethanol extract of *C. spectabilis* leaves could inhibit growth of rodent malaria parasite *P. berghei* by 59.29 % (at a dose of 100 mg/kg bodyweight). However, further investigation is required to determine an effective dose of the administered extract for a higher inhibitory effect and increasing effectiveness of the extract.

Material and Methods: To determine the effective dose of ethanol extract of *C. spectabilis* leaves, a "4-day suppressive test" of Peter was performed with some modifications. The extract was administered orally to *P. berghei*-infected mice in multiple doses (twice and thrice daily) and single dose (once daily) with dose ranging from 50 - 250 mg/kg body weight. Antimalarial activities were determined by analyzing suppression of parasitaemia of treated mice.

Results: The results showed that oral administration of the ethanol extract of *C. spectabilis* leaves at dose of 150mg/kg bodyweight thrice daily possessed higher inhibition (62.42%) compared to those twice daily (52.58%) and once daily (46.25%).

Conclusion: These results suggested that ethanol extract of *C. spectabilis* is promising candidate for development of antimalarial drugs. The effective dose of the ethanol extract is 150 mg/kg bodyweight with thrice administration daily.

Keywords: *Cassia spectabilis*, antimalarial, *Plasmodium berghei*, *in vivo*

Introduction

Traditional medicines provide for about 80% of health care in world populations, especially in the developing countries (Bodeker and Kronenber, 2002). In addition, plant-derived compounds have played an important key role in drug discovery. Several plants including their isolated compounds have been reported to inhibit malaria parasite (Oliveira, 2009).

Malaria is currently a public health concern in many countries due to factors such as the emerge of resistance, poor hygienic conditions, poorly managed vector control programs and no available approved vaccines (Onguene et al., 2013).

Malaria is a disease that is transmitted through the bite of a female *Anopheles* mosquito, which is infected by protozoa of genus *Plasmodium*. It is still endemic in most parts of Indonesia (WHO, 2015). Elyazar et al., 2011 summarized the distribution of *P. falciparum*, *P. vivax*, *P. malariae*, and *P. ovale* among Indonesian population during the year of 1900-2009 was 5.8; 4.9; 0.2 and 0.005 % respectively. Those data showed that *P. falciparum* was the highest cause among the reported infection cases. The morbidity and mortality on malaria cases in Indonesia are routinely under-reported. The WHO estimated that there were 2.5 million cases of malaria in Indonesia in 2006 and over 3000 deaths had occurred in the year of 2006 (Elyazar et al., 2011).

Malaria eradication program has been carried out to suppress the morbidity and mortality caused by malaria, including early diagnosis, prompt treatment, proper surveillance and vector control. However, it also impacted on the increasing of drug resistance cases, (WHO, 2016). A new antimalarial drug to overcome such resistance is absolutely required.

Medicinal plants are potential resources for the search of antimalarial agents. Plants which are belonging to genus of *Cassia* have been reported possess strong inhibition against malaria parasite (Abdulrazak et al., 2015; Ekasari et al., 2009; Morita et al., 2007).

Cassia Linn. is a major genus of *Caesalpiniaceae* family. It has 600 species and some of which are widely distributed worldwide especially in tropical countries such as India (Dave and Ledwani, 2012; Viegas et al, 2004). They are also widely distributed in tropical and subtropical regions and have been used as traditional folk medicine, particularly for treatment of fever and malaria (Dave and Ledwani, 2012).

Other study reported on the chemical constituents of genus *Cassia*. The secondary metabolites of *C. spectabilis*, *C. siamea*, *C. fistula*, *C. biflora* and *C. hirsute* have been identified including alkaloids, tannins, saponins, flavonoids, carbohydrates, proteins, steroids, terpenoids, cardiac glycosides and phlobatannins (Usha and Bopaiah, 2011)

Our previous study has been reported on one of the plants from the genus *Cassia* in Indonesia, i.e. *C. siamea* that exhibited antimalarial activity. The isolated compound, namely Cassiarin A, revealed to effectively inhibit the growth of malaria parasites with IC₅₀ value of 0.005 µg / mL and ED₅₀ value of 12.17 mg/kg body weight (Morita et al, 2007; Ekasari et al., 2009).

Our previous screening on antimalarial activities of different nine plant species from the genus of *Cassia* showed that *C. spectabilis* produced the highest inhibition against malaria parasite (Ekasari et al, 2015). *In vitro* analysis revealed that methanol extract of leaves from *C. spectabilis* showed the strongest antimalarial activity against *P. falciparum* with IC₅₀ value of 2.66 µg/mL. Moreover, its ethanolic extract also inhibits the growth of the *P. berghei* *in vivo* by 59.29% (at dose of 100 mg/kg bodyweight). Further investigation on possible compounds which contributed to its antimalarial activities, revealed that only leaves of *C. spectabilis* possess an alkaloid compounds (Ekasari et al., 2009). However, other study also reported the isolated compounds from *C. spectabilis* including beta-sitosterol, betulinic acid, caffeine, dihidroksi calamenen, 1,8-dihidroksi-3-metyl-6-metoksi antraquinon, friedelin, oleanolic acid, alkaloid piperidin, spectraline, stigmasterol; 1,3,8-trihidroksi-2-methylantraquinone and ursolic acid (Subramanian et al., 2012).

Determination of an effective dose that causing a higher inhibitory effect is needed before the extract can be used as an antimalarial drug. First step is to define ED₅₀ value of the ethanolic extract of *C. spectabilis* leaves against *P. berghei* in mice by giving the *P. berghei*-infected mice with the extract based on Munos et al (2000). Further, based on this value the extract will be given in a single and multiple doses. The multiple doses are given to extend the therapeutic activity of the extract. Plasma level of the drug is maintained as therapeutic range to achieve its maximal effectivity, therefore, multiple doses are given in order to maintain its plasma level relatively constant. The rules of drug dosing is to give the ideal plasma level without any fluctuation and excessive accumulation of the drug (Shargel et al., 2005).

Materials and Methods

Plant Material

The leaves of *C. spectabilis* were collected from Purwodadi Botanical Garden, East Java, Indonesia and specimen was deposited as the herbarium (Number : 525/IPH.3.04/HM/IV/2015)

Rodent's parasite

The chloroquine sensitive *P. berghei* ANKA strain was obtained from Institute of Biomolecular Eijkmann, Jakarta, Indonesia. Mice were maintained at Malaria Laboratory, Faculty of Pharmacy, Airlangga University, Indonesia. The percentage of parasitaemia of mice donor was examined through gram staining of mice-infected blood. Blood was collected from the mice with high parasitaemia and deposited for the use of next infection.

Inoculum of erythrocytes infected with *P. berghei* was prepared by determining the percentage parasitaemia of mice donor and diluting the blood with alceivers solutions with predetermined proportion. The mice were infected intraperitoneally with 200µL of 5% parasite-containing blood from frozen deposits. Once the percent of parasitaemia reached 20%, the mice blood was taken intracardially and diluted with PBS up to 1% parasitaemia. The test mice were further infected with 200µL of this parasite-containing blood with 1% parasitaemia (Widyawaruyanti et al., 2014).

Animals

Adult male Balb-C mice with 20-30 g bodyweight were obtained from Pusat Veterinaria Farma (PUSVETMA) Surabaya. The mice were fed with mice pellet diet and given free access to clean drinking water. The animals allowed to acclimatize for two weeks before treated. The permission and approval for animal studies were obtained from Faculty of Veterinary Medicine, Airlangga University.

Preparation of Extract

The leaves of *C. spectabilis* were cleaned, shade dried for four days and pulverized to produce powder. One kilogram of the dried leaf powder was extracted with 5 L of 90% ethanol using maceration method.

Antimalarial Activity

Antimalarial activities were performed by *in vivo* experiment in mice. In order to determine ED₅₀, animals were divided into seven groups of five mice, one was negative control group and six were treated groups. The negative control group was given CMC Na 0,5% once a day orally, and treated groups were fed with suspension of 90% ethanol extract of *C. spectabilis* leaves with the dose of 50, 75, 100, 150, 200 and 250 mg/kg body weight of mice once a day orally.

Further investigation to determine the effective dose of extract was also performed. Two kind of experiments were conducted in parallel. First, the ethanol extract of *C. spectabilis* leaves was administered in multiple doses (twice and thrice daily). Second, it was administered in single dose (once daily) orally at a dose of 150 mg/kg of body weight.

Antimalarial activity of ethanol extract of *C. spectabilis* leaves were conducted by 4-day suppressive test of Peters (Phillipson and Wright, 1991). Each mouse was inoculated intraperitoneally on the first day (day 0/ D0) with 0.2 ml of *P. berghei*-infected blood (1%), and followed by treatment of the malarial- infected mouse with ethanol extract of *C. spectabilis* in concentration of 50, 75, 100, 150, 200 or 250 mg/kg bodyweight. The extract was administered orally for four consecutive days.

On the fourth day after treatment (D4), the percentage of parasitaemia in *P. berghei*-infected mouse was evaluated by collecting blood from the tail of mice, and the parasitaemia was examined by gram staining. Parasitaemia level was determined by counting the number of parasite-infected erythrocytes per 3000 erythrocytes, and the ED₅₀ was calculated by probit analysis.

The ED₅₀ representing 50% suppression of parasite when it is compared to untreated control. Average percentage of parasite's inhibition was calculated as following :

$$100\% - \left(\frac{X_e}{X_k} \times 100 \right)$$

X_e = % parasitaemia growth of the treated

X_k = % parasitaemia growth of negative control

Results

The results of *in vivo* antimalarial activity of ethanol extract of *C. spectabilis* leaves against *P. berghei* is presented in Table 1, Table 2 and Table 3. The percentage of parasitaemia was observed from day 0 to day 4 post treatment (Table 1).

Table 1: The percentage parasitaemia value of mice infected-*P. berghei* treated with ethanol extract of *C. spectabilis* leaves per orally

Sample (mg/kg body weight)	Average parasitemia (%)				
	D ₀	D ₁	D ₂	D ₃	D ₄
Neg. control	1.22±0.71	5.24±2.52	5.59±3.56	16.54±4.28	21.77±4.83
50	1.57±2.16	3.28±2.27	6.57±3.23	11.15±2.56	15.74±3.14
75	2.11±1.47	3.83±2.94	6.02±3.54	10.93±4.05	15.85±4.61
100	1.88±1.57	4.35±3.85	7.49±6.32	10.48±6.27	13.47±6.40
150	1.30±1.23	4.34±2.60	5.73±2.69	7.11±2.18	11.29±3.21
200	1.26±0.75	3.95±1.39	4.69±0.99	8.16±3.83	9.89±2.70
250	0.51±0.40	2.51±0.99	4.64±0.96	5.92±1.70	6.90±1.67

Data were obtained from average of 5 replications. D₀-D₄: Observation of percentage parasitaemia from day 0 (D0) until Day 4 (D4) post treatment.

The percentage parasitaemia of negative control was dramatically increased after three day (D3) and four day (D4) post treatment with parasitaemia level of 16.54±4.28% and 21.77±4.83%, respectively. A significant reduction of parasitaemia was observed by treatment at dose of 150 mg/kg body weight in D4 which showed percentage inhibitory of 51.38±12.58 % (Table 2). The result indicated that the dose of 150mg/kg bodyweight of extract possess strong inhibition against *P. berghei*.

Table 2: The average percentage of growth and the inhibition of mice infected-*P. Berghei* treated with ethanol extract of *C. spectabilis* leaves perorally.

Sample (mg/kg body weight)	Average percentage of growth	Average percentage inhibition	ED ₅₀ (mg/kg bodyweight)
Negative control	20.55± 5.01	-	131,5
50	14.17± 3.25	31.05 ± 15,82	
75	13.74± 3.55	33.13 ± 17,26	
100	11.59± 6.07	43.60 ± 29,56	
150	9.99± 2.59	51.38 ± 12,58	
200	8.62± 2.18	58.04 ± 10,59	
250	6,39± 1.82	68,91 ± 8,84	

Data were obtained from 5 replications.

Further analysis to determine the effective dose showed that multiple dose administration daily produced higher inhibition with percentage inhibitory of 52.58± 7.18 and 62.42±1,62 %, (twice and thrice daily respectively). Those were higher than the single administration which was 46.25±3.83% (Table 3).

Table 3: *In vivo* inhibition of mice infected-*P. berghei* treated with ethanol extract of *Cassia spectabilis* leaves at single dose(150 mg/kg body weight) and multiple dose (2 x150 mg/kg body weight and 3 x 150 mg/kg body weight) during 4 days

Sample mg/kg bodyweight	Rep	D0	D4	Percentage of growth	Average of percentage growth	of percentage inhibition	Average of percentage inhibition
Negative control	1	1.25	8.28	7.03	7.03± 1.18	-	-
	2	0.55	10.07	9.52			
	3	2.48	8.84	6.36			
	4	1.29	8.32	7.03			
	5	0.77	7.01	6.24			
	6	1.28	7.28	6.00			
150	1	2.17	6.37	4.20	3.78± 0.27	40.26	46.25±3.83
	2	1.40	5.35	3.95			
	3	1.32	5.17	3.85			
	4	2.25	5.68	3.43			
	5	1.75	5.53	3.78			
	6	1.62	5.08	3.46			
2x 150	1	3.12	5.57	2.45	3.33± 0.50	65.15	52.58± 7.18
	2	1.54	4.81	3.27			
	3	0.94	5.13	4.19			
	4	1.91	5.22	3.31			
	5	1.61	5.04	3.43			
	6	1.83	5.16	3.33			
3x150	1	1.94	5.10	3.16	2,64± 0.29	55.05	62.42±1,62
	2	1.66	4.50	2.66			
	3	1.73	4.36	2.63			
	4	0.99	3.58	2.59			
	5	1.62	4.42	2.62			
	6	1.89	4.08	2.19			

Discussion

Medicinal plants are potential resources for antimalarial agent. Preliminary study of *C. spectabilis* reported the antimalarial activities of this plant and proved to be a promising candidate for antimalarial agent. Further analysis was conducted in this study to determine the effectiveness of ethanol extract of *C. spectabilis* in the animal test.

In vivo analysis to *P. berghei*-infected mice was conducted by adopting method of Munoz et al. (2000) which applied some dose modification. The *P. berghei*-infected mice were treated with *C. spectabilis* extract in dose range of 50-250 mg/kg body weight. The results showed dose dependent mode of inhibition and 50% inhibition was obtained by the dose of ≤150 mg/kg bodyweight (Table 1 and 2). The dose of 250 mg/kg produced the highest inhibitory (68.91%), while those that received 200 and 150 mg/kg body weight exhibited inhibitory of 58.04 ± 10,59% and 51.38 ± 12,58%, respectively (Table 2). These results suggested that ethanol extract of *C. spectabilis* leaves can be categorized as good antimalarial activity, with >50% inhibitory effect achieved at dose of 250 mg/kg (Munoz et al., 2000). Other study

(Bantie et al.,2014), classified extracts which have more than 50% percentage inhibitory value in *in vivo* antimalarial test with doses of 500, 250 and 100 mg/kg of body weight as moderate, good and excellent activity, respectively.

According to those classifications, the activity of ethanol extract of *C. spectabilis* leaves can be classified as good antimalarial activity. The ED₅₀ of ethanol extract of *C. spectabilis* was 131.5 mg/kg body weight (Table 2). Therefore, the dose of 150 mg/kg body weight was used to determine the effectiveness as antimalarial agent.

The study was continued by investigating the administration of ethanol extract of *C. spectabilis* in multiple-dose and single dose with dose of 150 mg/kg body weight. The result showed that the growth percentage of *P. berghei* for multiple doses (2 or 3 times a day) were lower than single dose. The lowest growth shown for thrice daily. This means that the extract administered in multiple doses is more effective inhibiting the growth of the parasite compared to single dose. Multiple doses administration could maintain the optimal or therapeutic concentration in blood and inhibit parasite in the various stage of parasite's life cycle. This provides availability of drugs in blood longer so that the therapeutic effect can be maintained.

Conclusion

C. spectabilis is potential candidate for antimalarial agent. The antimalarial effective dose of ethanol extract of *C. spectabilis* leaves in *P.berghei*-infected mice is 150 mg/kg bodyweight with thrice daily administration.

Conflict of Interest: The authors declare that they have no conflict of interest.

Acknowledgements: This research was funded by Directorate of Higher Education Indonesia (DIKTI), 2016.

References

1. Abdulrazak N, Asiya UI, Usman NS, Unata IM, Farida A, (2015). Anti-plasmodial activity of ethanolic extract of root and stem bark of *Cassia sieberiana* DC on mice, Journal of Intercultural Ethnopharmacology Apr-jun; 4 (2) : 96-101
2. Alaíde B. Oliveira, Maria Fâni Dolabela' Fernão C. Braga' Rose L.R.P. Jácome' Fernando P. Varotti' Marinete M. Póvoa' (2009). Plant-derived antimalarial agents: new leads and efficient phythomedicines. Part I. Alkaloids. Anais da Academia Brasileira de Ciências. Vol.81. 4.
3. Bantie L, Assefa S, Teklehaimanot T, Engidawork E. (2014). *In vivo* antimalarial activity of the crude leaf extract and solvent fractions of *Croton macrostachyus* Hocsht (Euphorbiaceae) against *P. berghei* in mice. BMC Complementary and Alternatif Medicine **14**:79.
4. Bodeker G, Kronenberg F. (2002). A Public health agenda for traditional, complementary, and alternative medicine. American Journal of Public Health. 92:1582–91.
5. Dave H and Ledwani L. (2012). A Review on anthraquinones isolated from *Cassia* species and their applications. Indian Journal of Natural Products and Resources. **3**: 291-319.
6. Elyasar IRF, Hay SI, Baird JK, Malaria distribution, prevalence, drug resistance and control in Indonesia. (2011), Advances in Parasitology.**74**:41-175
7. Ekasari W, Widyawaruyanti W, Zaini NC, Syafruddin, Honda T, and Morita H. (2009). Antimalarial activity of cassiarin A from the leaves of *Cassia siamea*.Heterocycles.**78**: 1831-1836.
8. Ekasari W, Wahyuni TS, Satyo Y RA. (2015). Potential anti-malaria and microscopic- phytochemical examination of leaves of some plants Cassia Genus. Journal Farmasi dan Ilmu Kefarmasian Indonesia. **2**:48-52.
9. Morita H, Oshimi S, Hirasawa Y, Koyama K, Honda T, Ekasari W, Indrayanto G and Zaini NC. (2007). Cassiarin A and B, novel antiplasmodial alkaloids from *Cassia siamea*. Organic Letters. **9**: 3691-3693.
10. Munoz V, Sauvin M, Bourdy G, Callapa J, Rojas I, Vargas L, Tae A, Deahro E. (2000). The search for natural bioactive compounds through a multidisciplinary approach in Bolivia. Part II. Antimalarial activity of some plants used by Mosekene Indians. Journal Ethnopharmacology. **69**:139-155
11. Onguene PA, Ntie -Kang F, Lifongo LL, Ndom JC, Sippl W, Mbaze LM. (2013). The potential of anti-malarial compounds derived from African medicinal plants. Part I: A pharmacological evaluation of alkaloids and terpenoids, Malaria Journal.**12**:449
12. Phillipson JD and Wright CW. (1991). Antiprotozoal agents plant sources. Planta Medica. **57**: 53 – 59
13. Shargel L, Wu-Pong S, Yu AB. (2005). Applied biopharmaceutics and pharmacokinetics. 5th.Ed. Boston:Mc Graww Hill.
14. Subramanian L. Jothy, Torey A, Darah I, Choong Y.S, Saravanan D, Chen Yeng, Latha L.Y, Deivanai S, Sasidharan S. (2012). *Cassia spectabilis* (DC) Irwin et Barn: A promising traditional herb in health improvement.Molecules.**17**: 10292-10305.
15. Usha Veerachari, Bopaiah A.K. (2011). Preliminary phyto-chemical evaluation of the leaf extract of five *Cassia* species. Journal of Chemical and Pharmaceutical Research. **3**: 574-583
16. Viegas, J.R.C.; Bolzani, V.S.; Furlan, M. Barreiro, EJ.; Young, M.C.M.; Tomazela D.M.; Eberlin, M.N. (2004). Further bioactive piperidine alkaloids from the flowers and green fruits of *Cassia spectabilis*. Journal of Natural Products.**67**: 908-910.
17. WHO: World malaria report. (2015). Geneva: World Health Organization, available from http://who.int/malaria/publications/country-profiles/profile_idh_en.pdf (accessed on September 27, 2016).

18. WHO: Malaria Case Management: Operation manual, available from http://www.who.int/malaria/publications/atoz/malaria_case_management_operation_manual.pdf (accessed on September 27, 2016).
19. Widyawaruyanti A, Asrory M, Ekasari W, Setiawan D, Radjaram A, Tumewu L, Hafid A.F. (2014). *In vivo* antimalarial activity of *Andrographis paniculata* tablet. *Procedia Chemistry*.**13**:101-104.